Publication Name	World Journal of Diabetes
Manuscript ID	54009
Country	Greece

Received	2020-01-04 11:30
Peer-Review Started	2020-01-04 11:32
To Make the First Decision
Return for Revision	2020-02-25 21:20
Revised	2020-02-29 10:29
Second Decision	2020-04-04 06:37
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-04-05 16:12
Articles in Press	2020-04-05 16:12
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2020-04-23 23:50
Publish the Manuscript Online	2020-05-11 09:58

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Editorial
Article Title	Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus
Manuscript Source	Invited Manuscript
All Author List	Stelina Alkagiet and Konstantinos Tziomalos
Funding Agency and Grant Number
Corresponding Author	Konstantinos Tziomalos, MD, MSc, PhD, Associate Professor, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 1 Stilponos Kyriakidi Street, Thessaloniki 54636, Greece. ktziomalos@yahoo.com
Key Words	Heart failure; Type 2 diabetes mellitus; Sodium-glucose co-transporter-2 inhibitors; Canagliflozin; Dapagliflozin; Empagliflozin
Core Tip	Sodium-glucose co-transporter-2 inhibitors substantially reduce the risk of hospitalization for heart failure (HF) in patients with type 2 diabetes mellitus (T2DM). Accordingly, these agents should be considered in all patients with T2DM and HF with reduced left ventricular ejection fraction regardless of HbA1c levels. However, more studies are needed to clarify the role of sodium-glucose co-transporter-2 inhibitors in patients with T2DM and HF with preserved left ventricular ejection fraction, which is the commonest type of HF in this population.
Publish Date	2020-05-11 09:58
Citation	Alkagiet S, Tziomalos K. Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus. World J Diabetes 2020; 11(5): 150-154
URL	https://www.wjgnet.com/1948-9358/full/v11/i5/150.htm
DOI	https://dx.doi.org/10.4239/wjd.v11.i5.150

Full Article (PDF)	WJD-11-150.pdf
Full Article (Word)	WJD-11-150.docx
Manuscript File	54009-Review.doc
Answering Reviewers	54009-Answering reviewers.pdf
Audio Core Tip	54009-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	54009-Conflict-of-interest statement.pdf
Copyright License Agreement	54009-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	54009-Language certificate.pdf
Peer-review Report	54009-Peer-review(s).pdf
Scientific Misconduct Check	54009-Scientific misconduct check.pdf
Scientific Editor Work List	54009-Scientific editor work list.pdf